RAS inhibitor

REDWOOD CITY, Calif., August 26, 2026 Revolution Medicines, Inc. has received U.S. Food and Drug Administration (FDA) approval for...

Revolution Medicines, Redwood City, Calif., July 22, 2026 Revolution Medicines announced that the U.S. Food and Drug Administration (FDA)...

PRINCETON, N.J., June 1, 2026 Bristol Myers Squibb has achieved a significant regulatory milestone after the U.S. Food and...

REDWOOD CITY, Calif., May 31, 2026 Revolution Medicines has announced unprecedented results from its pivotal Phase 3 RASolute 302...

Redwood City, Calif., May 6, 2026 Revolution Medicines, Inc. announced the publication of important Phase 1/2 clinical trial data...

REDWOOD CITY, Calif., April 2, 2026 Revolution Medicines has announced the initiation of patient dosing in its global Phase...